Venus Remedies has launched a novel formulation, ‘Achnil’ — a brand of aceclofenac injection in India.
Commenting on the development, the company Joint Managing Director, Ms Manu Chaudhry, said: “This novel formulation based on NDDS (Novel Drug Delivery System) technology will fill in the gap of long-standing demand for better pain management therapies, especially for the aged population.”
She further added that the product would not only reduce the number of pricks, but will also drastically reduce the side-effects associated with the use of non-steroidal, anti-inflammatory drugs (NSAIDs).
According to the firm, the new product gives instant relief from acute pain and is effective for the next 24 hours against the conventional daily dose of three injections of diclofenac given every eight hours.
The company said it took more than seven years for the successful completion of phase-I, phase-II and phase-III clinical trials and regulatory approvals from DCGI for this product.
Apart from India, the company also plans to launch the product in other markets worldwide.
Meanwhile, the shares of Venus Remedies were being quoted at Rs 192 in the late afternoon trade on the Bombay Stock Exchange today, up 0.42 per cent from the previous close.